BOECILLO, Spain — European contract development and manufacturing organization (CDMO) 53Biologics has announced a significant expansion of its production infrastructure with a €2 million ($2.25 million) investment in advanced lyophilization capabilities. The move, centered at the company’s cGMP facility in Boecillo, Spain, marks a strategic effort to enhance the stabilization and manufacturing of next-generation biologic therapies.
Central to this investment is the installation of a 1.8 m² Telstar Lyomonic 2 ST lyophilizer. By bringing freeze-drying operations in-house, 53Biologics is set to significantly bolster its fill-finish efficiency, with the capacity to process up to 10,000 2R vials per batch. This technology is critical for modern medicine, as it provides the necessary stability and extended shelf life required for increasingly complex biological products, including plasmid DNA and recombinant proteins.
While the new equipment has already been successfully utilized to produce initial preclinical batches, the company confirmed that the facility is on track to be fully operational for cGMP manufacturing by early 2027.
“Adding lyophilization to our in-house fill-and-finish capabilities is an important step in the evolution of 53Biologics’ service offering,” said CEO Pablo Gutiérrez. According to Gutiérrez, the investment is designed to satisfy shifting clinical and regulatory demands while simplifying the supply chain for clients. By centralizing these services, 53Biologics aims to function as a comprehensive “one-stop-shop,” allowing biotechnology partners to manage multiple phases of production through a single entity.
This latest project builds on a sustained multi-year commitment to upgrading the Boecillo site. In recent years, the company has integrated a series of high-specification technologies, including a Grade A isolator, closed-system filling infrastructure, and semi-automated crimping and labeling systems. These investments are supported by a robust suite of analytical laboratories that provide the necessary testing to ensure regulatory compliance throughout the development lifecycle.
The expansion is particularly timely as the demand for advanced, sensitive biologic drugs continues to accelerate. By consolidating essential manufacturing and finishing services, 53Biologics is positioning itself to better support clients from the early stages of clinical trials through to commercialization.
While the new in-house lyophilization suite will handle a significant portion of project demand, 53Biologics notes that it will continue to leverage a curated network of specialized partners to provide additional flexibility and niche fill-finish technologies when required. This hybrid model, combined with the new in-house infrastructure, underscores the company’s objective to remain a highly responsive partner in the competitive European biologics market.
As the site prepares for its 2027 cGMP certification, 53Biologics remains focused on scaling its technical expertise to meet the needs of a global clientele, further solidifying its standing as a key player in the European biopharmaceutical manufacturing landscape.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
